Lomma, Sweden

David Liberg


 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Vintrie, SE (2018)
  • Lomma, SE (2017 - 2024)

Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Inventor David Liberg: Innovating in Antibody Therapeutics

Introduction

David Liberg is a prominent inventor based in Lomma, Sweden, known for his significant contributions to the field of therapeutic antibodies. With a total of 8 patents to his name, Liberg's innovations primarily focus on the treatment and diagnosis of diseases associated with Interleukin 1 Receptor Accessory Protein (IL1RAP).

Latest Patents

Among David Liberg's latest patents are the formulations related to Anti-IL1RAP antibody compositions. These inventions emphasize the use of antibody compositions directed at IL1RAP for addressing various diseases, including inflammatory, autoimmune, autoinflammatory, and neoplastic disorders. The inventions also detail an antibody or antigen-binding fragment with specificity for IL1RAP, the polynucleotide encoding the antibody, and methods for producing these antibodies. Additionally, these patents encompass a composition involving the antibody, polynucleotide, vector, and host cell, which may potentially be invaluable in the medical field for both treatment and diagnosis.

Career Highlights

Throughout his career, David Liberg has worked with notable companies in the biopharmaceutical sector. His positions at Active Biotech AB and Cantargia AB reflect his commitment to advancing medical innovations. These roles have allowed him to develop crucial therapeutic solutions that leverage his expertise in antibody technology.

Collaborations

In his journey as an inventor, David Liberg has collaborated with esteemed professionals in the field, including Stephen East and Natacha Prevost. Their combined efforts have contributed to push boundaries in the potential treatments for diseases linked to IL1RAP.

Conclusion

David Liberg stands as a key figure in the realm of antibody-based therapeutics. With his ongoing research and dedication, he continues to shape the future of medical treatments, aiming to alleviate the burden of diseases associated with IL1RAP. His work exemplifies the critical role of innovation in enhancing healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…